[Hyperhomocysteinemia during pregnancy as a risk factor of preeclampsia]

Eva López-Quesada1, Eva Also-Rayo, M Antonia Vilaseca

  • 1Servicio de Ginecología y Obstetricia, Hospital Universitari San Joan de Déu, Esplugues de Llobregat, Barcelona, España.

Medicina Clinica
|September 23, 2003
PubMed

A revision about the role of hyperhomocysteinemia in the development of preeclampsia is presented, which summarises our experience in different biochemical and genetic points in relation to this possible association. Plasma total homocysteine concentrations (tHcy) during pregnancy were significantly lower than those of non-pregnant women: 2nd trimester (median, 5.3 micromol/l; range, 3.1-10.0 micromol/l); 3rd trimester (median, 6.3 micromol/l; range, 3.2-13.0 micromol/l). Hyperhomocysteinemia (tHcy>P95) was established as values higher than 7.7 micromol/l in the 2nd trimester, and as values higher than 10.5 micromol/l in the 3rd trimester of pregnancy. We found an association between hyperhomocysteinemia and preeclampsia: tHcy values were significantly higher in the preeclamptic group than in uncomplicated pregnancies; the OR for preeclampsia in hyperhomocysteinemic patients was 7.7 (CI 95%, 1.7-34.8). The other amino acid concentrations were also higher in preeclamptic women. The negative correlation observed between homocysteine and folate in the control group, was not present in preeclamptic women. An association between homocysteine concentrations in preeclampsia and glucose intolerance was not observed. The Doppler study of uterine artery flow velocity waveforms seems to be a good screening method to identify pregnancies at high risk of preeclampsia. The addition of homocysteine determination did not usefully improve its predictive value. The polymorphisms in the main genes involved in folate-homocysteine metabolism studied could not be considered as the determinants of the hyperhomocysteinemia observed in preeclamptic pregnants.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...